:The present study evaluates the cranio‑facial growth disorders in a series of patients suffering from pituitary dwarfism, as a result of the therapy with recombinant human growth hormone (rhGH). Included in the study were 15 children diagnosed with pituitary dwarfism in the Endocrinology Clinics of the �Sf. Spiridon� Hospital of Iasi, subjected to a treatment with rhGH for 2 years. After the application of the therapy, the parameters of general physical development were followed and the dental orthopantomography and profile cephalometry were analyzed.
The results obtained confirm a general physical growth of about 1.3 cm/month in the first year of treatment, followed by values around 1.1 cm/month in the second year. Cranio‑facial development was improved by the increase of both mandibular vertical branch and facial height. At the level of the dental arches, one could observe improved sagital and transversal relations at molar level, as well as a regulating tendency of dental eruption. The therapy with rhGH is thus influent at cranio‑facial level, favourizing the development of maxillaries, regulation of dental eruption and the aesthetic aspects.